Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vignesh Rajah Insider Profile
4 Followers
Vignesh Rajah, SVP & CMO at Y-Mabs Therapeutics, holds 38.16K shares in Y-Mabs Therapeutics (Ticker: YMAB). Most recently, Vignesh Rajah Sold $1,711 shares of Y-Mabs Therapeutics on Mar 07, 2024 for an estimated value of 28.28K.
Profitable Transactions
2 out of 4 Profitable Transactions
Average Return
-13.50%
Average return per transaction
Time Frame
Compare to
Insider Roles
SVP & CMO
Roles that Vignesh Rajah holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Nov 16, 2022 - Nov 16, 2023
Return:+34.40%
The most profitable trade made by Vignesh Rajah
Vignesh Rajah's Trading History
List of latest transactions for each holding click on a transaction to see Vignesh Rajah's performance on stock
You May Also Like
Vignesh Rajah insider profile FAQ
What is the percentage of profitable transactions made by Vignesh Rajah?
The percentage of profitable transactions made by Vignesh Rajah is 50%.
What is the average return per transaction made by Vignesh Rajah?
The average return per transaction made by Vignesh Rajah is -13.50%.
What stocks does Vignesh Rajah hold?
Vignesh Rajah holds: YMAB stocks.
What was Vignesh Rajah’s latest transaction?
Vignesh Rajah latest transaction was an Informative Sell of $28.28K.
What was Vignesh Rajah's most profitable transaction?
Vignesh Rajah’s most profitable transaction was an Informative Buy of YMAB stock on November 16, 2022. The return on the trade was 34.40%.
What is Vignesh Rajah's role in Y-Mabs Therapeutics?
Vignesh Rajah's role in Y-Mabs Therapeutics is SVP & CMO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.